This Leukine market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historical period can be attributed to an increase in cancer cases, rising awareness of the benefits of GM-CSF, favorable regulatory approvals, improvements in healthcare infrastructure, and an aging population.
Growth during the market's forecast period is expected to be driven by the rising demand for cancer treatments, the expansion of indications, improved patient outcomes, greater adoption in emerging markets, and strategic collaborations and partnerships. Key trends for the forecast period include advancements in cancer therapies, the development of new formulations, personalized medicine, advanced delivery systems, and innovations in biologic drugs.
The growing incidence of leukemia is expected to drive the expansion of the leukine market in the coming years. Leukemia is a cancer that affects the blood and bone marrow, resulting in the abnormal production of white blood cells. The rising incidence of leukemia can be attributed to factors such as environmental exposures, genetic mutations, lifestyle changes, and improved detection methods. Leukine aids leukemia patients by stimulating the production and activation of white blood cells, particularly neutrophils, to boost the immune response and accelerate recovery after chemotherapy or bone marrow transplants. This helps reduce the risk of infection and improve overall treatment outcomes. For example, in 2024, the American Cancer Society reported a rise in leukemia cases to 62,770, up from 59,610 in 2023. Therefore, the increasing incidence of leukemia is a driving factor for the growth of the leukine market.
A key trend in the leukine market is the expansion of administration routes to improve patient convenience, enhance compliance, and optimize therapeutic results. This expansion focuses on offering easier administration options while maintaining the drug’s therapeutic efficacy. For instance, in April 2024, Partner Therapeutics Inc., a US-based biotech company, announced that its partner, Nobelpharma, a Japanese pharmaceutical company, received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the inhaled use of Leukine (branded as Sargmalin in Japan) to treat autoimmune pulmonary alveolar proteinosis (aPAP). This approval marks the first regulatory authorization for an inhaled recombinant GM-CSF product for this condition, highlighting the broader therapeutic applications of leukine beyond its traditional uses in oncology and radiation exposure scenarios.
In March 2022, Tanner Pharma Group, a US-based provider of access solutions for essential medicines, partnered with Partner Therapeutics to increase local inventories of Leukine (sargramostim) in Europe. This collaboration aims to enhance emergency preparedness by ensuring the rapid availability of leukine in the event of radiation or chemical exposure, thereby strengthening response capabilities in potential crises. Partner Therapeutics is a US-based biopharmaceutical company.
The key company operating in the leukine market is Partner Therapeutics Inc.
North America was the largest region in the leukine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leukine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the leukine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Leukine (sargramostim) is a medication designed to stimulate the production of white blood cells, especially following chemotherapy or bone marrow transplants. It works by encouraging the growth of granulocytes and macrophages, which helps prevent infections in patients with weakened immune systems.
The primary formulations in the leukine market include injectable formulations (lyophilized powder) and ready-to-use solutions. Leukine’s injectable formulation is a lyophilized powder that, when reconstituted, contains sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). It can be administered through subcutaneous injection or intravenous infusion, and it is used for various indications, including the treatment of acute myeloid leukemia (AML), bone marrow suppression, neutropenia, and as supportive care for cancer patients. The patient demographics include adults, pediatric patients, and geriatric patients, with key end users including hospitals, oncology clinics, hematology clinics, and research institutions.
The leukine market research report is one of a series of new reports that provides leukine market statistics, including leukine industry global market size, regional shares, competitors with a leukine market share, detailed leukine market segments, market trends, and opportunities, and any further data you may need to thrive in the leukine industry. This leukine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The leukine market consists of sales of leukine injections, and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historical period can be attributed to an increase in cancer cases, rising awareness of the benefits of GM-CSF, favorable regulatory approvals, improvements in healthcare infrastructure, and an aging population.
Growth during the market's forecast period is expected to be driven by the rising demand for cancer treatments, the expansion of indications, improved patient outcomes, greater adoption in emerging markets, and strategic collaborations and partnerships. Key trends for the forecast period include advancements in cancer therapies, the development of new formulations, personalized medicine, advanced delivery systems, and innovations in biologic drugs.
The growing incidence of leukemia is expected to drive the expansion of the leukine market in the coming years. Leukemia is a cancer that affects the blood and bone marrow, resulting in the abnormal production of white blood cells. The rising incidence of leukemia can be attributed to factors such as environmental exposures, genetic mutations, lifestyle changes, and improved detection methods. Leukine aids leukemia patients by stimulating the production and activation of white blood cells, particularly neutrophils, to boost the immune response and accelerate recovery after chemotherapy or bone marrow transplants. This helps reduce the risk of infection and improve overall treatment outcomes. For example, in 2024, the American Cancer Society reported a rise in leukemia cases to 62,770, up from 59,610 in 2023. Therefore, the increasing incidence of leukemia is a driving factor for the growth of the leukine market.
A key trend in the leukine market is the expansion of administration routes to improve patient convenience, enhance compliance, and optimize therapeutic results. This expansion focuses on offering easier administration options while maintaining the drug’s therapeutic efficacy. For instance, in April 2024, Partner Therapeutics Inc., a US-based biotech company, announced that its partner, Nobelpharma, a Japanese pharmaceutical company, received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the inhaled use of Leukine (branded as Sargmalin in Japan) to treat autoimmune pulmonary alveolar proteinosis (aPAP). This approval marks the first regulatory authorization for an inhaled recombinant GM-CSF product for this condition, highlighting the broader therapeutic applications of leukine beyond its traditional uses in oncology and radiation exposure scenarios.
In March 2022, Tanner Pharma Group, a US-based provider of access solutions for essential medicines, partnered with Partner Therapeutics to increase local inventories of Leukine (sargramostim) in Europe. This collaboration aims to enhance emergency preparedness by ensuring the rapid availability of leukine in the event of radiation or chemical exposure, thereby strengthening response capabilities in potential crises. Partner Therapeutics is a US-based biopharmaceutical company.
The key company operating in the leukine market is Partner Therapeutics Inc.
North America was the largest region in the leukine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leukine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the leukine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Leukine (sargramostim) is a medication designed to stimulate the production of white blood cells, especially following chemotherapy or bone marrow transplants. It works by encouraging the growth of granulocytes and macrophages, which helps prevent infections in patients with weakened immune systems.
The primary formulations in the leukine market include injectable formulations (lyophilized powder) and ready-to-use solutions. Leukine’s injectable formulation is a lyophilized powder that, when reconstituted, contains sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). It can be administered through subcutaneous injection or intravenous infusion, and it is used for various indications, including the treatment of acute myeloid leukemia (AML), bone marrow suppression, neutropenia, and as supportive care for cancer patients. The patient demographics include adults, pediatric patients, and geriatric patients, with key end users including hospitals, oncology clinics, hematology clinics, and research institutions.
The leukine market research report is one of a series of new reports that provides leukine market statistics, including leukine industry global market size, regional shares, competitors with a leukine market share, detailed leukine market segments, market trends, and opportunities, and any further data you may need to thrive in the leukine industry. This leukine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The leukine market consists of sales of leukine injections, and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Leukine Market Characteristics4. Leukine Market Trends and Strategies5. Leukine Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Leukine Pricing Analysis & Forecasts30. Global Leukine Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Leukine Market32. Recent Developments in the Leukine Market
3. Leukine Market Biologic Drug Characteristics
6. Global Leukine Growth Analysis and Strategic Analysis Framework
8. Leukine Market Segmentation
9. Global Leukine Epidemiology of Clinical Indications
10. Leukine Market Regional and Country Analysis
11. Asia-Pacific Leukine Market
12. China Leukine Market
13. India Leukine Market
14. Japan Leukine Market
15. Australia Leukine Market
16. South Korea Leukine Market
17. Western Europe Leukine Market
18. UK Leukine Market
19. Germany Leukine Market
20. France Leukine Market
21. Eastern Europe Leukine Market
22. North America Leukine Market
23. USA Leukine Market
24. Canada Leukine Market
25. South America Leukine Market
26. Middle East Leukine Market
27. Africa Leukine Market
28. Leukine Market Competitive Landscape and Company Profiles
29. Global Leukine Market Pipeline Analysis
33. Leukine Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Leukine Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on leukine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for leukine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leukine market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Formulation: Injectable Formulation (Lyophilized Powder); Ready-to-Use Solutions2) by Route of Administration: Subcutaneous Injection; Intravenous Infusion
3) by Indication: Treatment of Acute Myeloid Leukemia (AML); Treatment of Bone Marrow Suppression; Treatment of Neutropenia; Supportive Care in Cancer Patients
4) by Patient Demographics: Adult Patients; Pediatric Patients; Geriatric Patients
5) by End User: Hospitals; Oncology Clinics; Hematology Clinics; Research Institutions
Key Companies Mentioned: Partner Therapeutics Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Partner Therapeutics Inc.
